MEVIS MEDSOL N - Dusseldorf Stock Exchang
MEVIS MEDSOL N - Dusseldorf Stock Exchang operates in Diversified Metals & Mining.
MEVIS MEDSOL N - Dusseldorf Stock Exchang (M3V) - Net Assets
Latest net assets as of March 2024: €17.83 Million EUR
Based on the latest financial reports, MEVIS MEDSOL N - Dusseldorf Stock Exchang (M3V) has net assets worth €17.83 Million EUR as of March 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€25.13 Million) and total liabilities (€7.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €17.83 Million |
| % of Total Assets | 70.93% |
| Annual Growth Rate | -9.53% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 16.45 |
MEVIS MEDSOL N - Dusseldorf Stock Exchang - Net Assets Trend (2017–2023)
This chart illustrates how MEVIS MEDSOL N - Dusseldorf Stock Exchang's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MEVIS MEDSOL N - Dusseldorf Stock Exchang (2017–2023)
The table below shows the annual net assets of MEVIS MEDSOL N - Dusseldorf Stock Exchang from 2017 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-09-30 | €17.83 Million | 0.00% |
| 2022-09-30 | €17.83 Million | 0.00% |
| 2021-09-30 | €17.83 Million | 0.00% |
| 2020-09-30 | €17.83 Million | 0.00% |
| 2019-09-30 | €17.83 Million | -44.40% |
| 2018-09-30 | €32.06 Million | -1.39% |
| 2017-09-30 | €32.51 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to MEVIS MEDSOL N - Dusseldorf Stock Exchang's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 80.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2023)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €4.54 Million | 25.47% |
| Other Components | €13.29 Million | 74.53% |
| Total Equity | €17.83 Million | 100.00% |
MEVIS MEDSOL N - Dusseldorf Stock Exchang Competitors by Market Cap
The table below lists competitors of MEVIS MEDSOL N - Dusseldorf Stock Exchang ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
The Yumy Candy Company Inc
OTCQB:YUMFF
|
$258.31K |
|
FRIO3F
SA:FRIO3F
|
$258.36K |
|
Prima Moda SA
WAR:PMA
|
$258.58K |
|
CBRAIN
BE:C6F
|
$258.58K |
|
Boussard & Gavaudan Holding Limited
LSE:BGHL
|
$257.95K |
|
UPSD
BATS:UPSD
|
$257.86K |
|
CompuLab Ltd
TA:CLAB
|
$257.82K |
|
ANGLO AMERICAN
MU:NGLB
|
$257.63K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MEVIS MEDSOL N - Dusseldorf Stock Exchang's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 17,826,021 to 17,826,021, a change of 0 (0.0%).
- Net income of 4,919,546 contributed positively to equity growth.
- Dividend payments of 7,789,048 reduced retained earnings.
- Other factors increased equity by 2,869,502.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €4.92 Million | +27.6% |
| Dividends Paid | €7.79 Million | -43.69% |
| Other Changes | €2.87 Million | +16.1% |
| Total Change | €- | 0.00% |
Book Value vs Market Value Analysis
This analysis compares MEVIS MEDSOL N - Dusseldorf Stock Exchang's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.59x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.42x to 2.59x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-09-30 | €17.86 | €25.40 | x |
| 2018-09-30 | €17.61 | €25.40 | x |
| 2019-09-30 | €9.79 | €25.40 | x |
| 2020-09-30 | €9.79 | €25.40 | x |
| 2021-09-30 | €9.79 | €25.40 | x |
| 2022-09-30 | €9.79 | €25.40 | x |
| 2023-09-30 | €9.79 | €25.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MEVIS MEDSOL N - Dusseldorf Stock Exchang utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 27.60%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 28.37%
- • Asset Turnover: 0.62x
- • Equity Multiplier: 1.57x
- Recent ROE (27.60%) is below the historical average (30.53%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 17.29% | 30.32% | 0.38x | 1.51x | €2.37 Million |
| 2018 | 22.37% | 42.79% | 0.44x | 1.20x | €3.97 Million |
| 2019 | 45.28% | 44.66% | 0.76x | 1.34x | €6.29 Million |
| 2020 | 32.00% | 33.30% | 0.62x | 1.56x | €3.92 Million |
| 2021 | 25.50% | 28.04% | 0.59x | 1.54x | €2.76 Million |
| 2022 | 43.69% | 41.52% | 0.60x | 1.75x | €6.01 Million |
| 2023 | 27.60% | 28.37% | 0.62x | 1.57x | €3.14 Million |
Industry Comparison
This section compares MEVIS MEDSOL N - Dusseldorf Stock Exchang's net assets metrics with peer companies in the Other industry.
Industry Context
- Industry: Other
- Average net assets among peers: $114,212,818,724
- Average return on equity (ROE) among peers: -9.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MEVIS MEDSOL N - Dusseldorf Stock Exchang (M3V) | €17.83 Million | 17.29% | 0.41x | $258.06K |
| HORIBA (01H) | $204.49 Billion | 10.42% | 0.82x | $989.01K |
| Tokyu Corporation (01T) | $779.37 Billion | 3.34% | 2.35x | $99.73K |
| GUANGZHOU AUTO -H- (02G) | $122.28 Billion | 6.59% | 0.55x | $4.05K |
| MOSAIC (02M) | $10.60 Billion | 4.43% | 0.90x | $280.83K |
| MOSAIC (02M.SG) (02M) | $9.56 Billion | 10.46% | 0.82x | $247.21K |
| CHINA JO-JO DRGSTRS (04CN.SG) (04CN) | $16.67 Million | -126.83% | 4.46x | $1.55 Million |
| KRAKATAU STEEL -B- (07K) | $552.59 Million | 3.52% | 4.72x | $166.99 |
| CN MODERN DAIRY (07M) | $7.12 Billion | -10.42% | 1.50x | $1.68K |
| TOURMALINE OIL (08T) | $7.22 Billion | 4.81% | 0.41x | $381.02K |
| ASIA CASSAVA RESOUR (0ACS) | $913.15 Million | 2.86% | 1.55x | $325.03 |